AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04059523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S6G5T-3
Description: once daily
Study NCT04059523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retin-A® 0.1% Cream
Description: once daily
Study NCT01188148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 5 mg per day of memantine
Study NCT01755559 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Artemether-lumefantrine
Description: antimalarial ACT
Study NCT03879265 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Noninvasive chromosome screening
Description: Screening based on MALBAC-NGS technology
Study NCT01188148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02952963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic Acid
Study NCT02952963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Study NCT00343083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erbitux, Paclitaxel & Carboplatin
Description: Paclitaxel, 40 mg/m2/week,~1-hour infusion (weeks 2-9.Paclitaxel will be administered on a weekly schedule at a dose of 40mg/m2 IV by 1-hour infusion prior to cetuximab dose.~Cetuximab: 400 mg/m2 IV (initial dose) week 1 then 250 mg/m2 IV weekly for 8 weeks weeks 2-9). Cetuximab will be administered 400mg/m2 IV on Day 1, then the first 250 mg/m2 IV dose will be given on day 8 (week 2) prior to carboplatin dose.~Carboplatin, AUC=2/week as a 30 minute infusion after cetuximab infusion (weeks 2-9)Carboplatin will be administered at a dose of AUC = 2/week IV bolus each week and will be administered prior to head and neck irradiation dose. (Carboplatin: AUC=2/week x 8 weeks (weeks 2-9)
Study NCT00343083 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: XRT=Radiotherapy 1.8 Gy radiation/day, 5 days a week for a total of 70.2 Gy.(weeks 2-9) - IMRT is allowed
Study NCT03112967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-volume preparation, oral sulfate solution
Description: Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
Study NCT03112967 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: large-volume preparation, 4L polyethylene glycol
Description: 4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy. And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
Study NCT02834208 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: quantitative measures of mRNA
Study NCT02834208 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: quantitative measures of mRNA
Study NCT02834208 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological assessment
Study NCT03062618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRCL-02
Description: Oral tablet(s) administered with water
Study NCT02834208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment
Study NCT03062618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Administered with water
Study NCT03088631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: will receive metformin (1500 mg/day) starting with the commencement of oral contraceptive pills in the preceding cycle until the day of human chorionic gonadotropin triggering.
Study NCT03088631 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: will receive corn-flour placebo tablets (three tablets daily).
Study NCT03466138 — intervention group
Intervention type: DEVICE
Intervention: PMD-200
Description: The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
Study NCT02728960 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI of the Brain (No Contrast) Scan
Description: DSI data will be acquired on 3T Tim Trio System (Siemens) using a 32-channel coil
Study NCT02728960 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI of the Brain (No Contrast) Scan
Description: DSI data will be acquired on 3T Tim Trio System (Siemens) using a 32-channel coil
Study NCT03286946 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: block with Blunt-type block needle.
Description: Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge blunt needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
Study NCT03286946 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: block with sharp-type block needle.
Description: Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge sharp needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
Study NCT03410797 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Inclusion of semi-occluded mask in voice therapy
Description: Patients will be given a facemask with a semi-occlusion (SOMask) for use during in person voice therapy and for use at home therapy practice.
Study NCT00463983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide
Study NCT00408096 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Copeland or Global CAP resurfacing prosthesis
Description: Both Copeland and Global Cap are uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact surfaces.
Study NCT03279913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG-neurofeedback training in association with TMS.
Description: EEG-neurofeedback training in association with TMS.
Study NCT02608580 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Survey
Study NCT00132795 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily monitoring of alcohol & drug use, & therapy skills
Description: Comparison(s): patients completing group CBT for substance abuse will be randomly assigned to two conditions. In one condition, patients will have unlimited access to the therapeutic telephone system for 4 months. The other condition is standard care (i.e., no formal relapse prevention).
Study NCT00132795 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: standard care (no added treatment)
Study NCT03032653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late Rehabilitation
Description: Post-0p: Non weight-bearing and no range of motion for 2 weeks post treatment. 2 weeks: Splint removed, removable pre-fabricated walking boot applied. WB as tolerated with boot, range of motion out of boot.~6 weeks: Boot discontinued and full unrestricted and unprotected WB and ROM permitted 6 weeks:
Study NCT03032653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Rehabilitation
Description: Weightbearing and range of motion as tolerated within the limitations of participant's own comfort. Use of ambulatory aides of any kind is permitted as needed without restriction. No brace or splint of any kind is permitted
Study NCT02876315 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Redoxon VI
Description: Each tablet contains:~Vitamin C (500mg) Vitamin A (1167IU) Vitamin B6 (3.3mg) Vitamin B12 4.8µg) Vitamin D (200IU) Vitamin E (22.5mg) Folic Acid (200µg) Zinc (5mg) Selenium (55µg) Copper (450µg) Iron (2.5mg)~Other ingredients: Microcrystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, hydroxypropylcellulose hypromellose, titanium dioxide, microcrystalline cellulose, iron oxide yellow, sodium croscarmellose, and talc
Study NCT02876315 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Ingredients: Microcrystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, hydroxypropylcellulose hypromellose, titanium dioxide, microcrystalline cellulose, iron oxide yellow, sodium croscarmellose, and talc
Study NCT03665233 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VR
Description: People in the VR-group get a VRH session during the CPM physiotherapy , people in the sham group get a VR sham session, while they both can enjoy Standard Treatment
Study NCT03665233 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VR
Description: People in the VR-group get a VRH session during the CPM physiotherapy , people in the sham group get a VR sham session, while they both can enjoy Standard Treatment
Study NCT01365468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Description: oral daily dosing of tablet starting with 2.5 mg
Study NCT04461457 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 211-astatine MX35 F(ab')2
Description: Alpha emitting radionuclide 211At conjugated to monoclonal antibody MX35 F(ab')2. Targeting the sodium phosphate transporter (NaPi2b).
Study NCT00523744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine supplied as 5 mg tablets, taken orally once a day during Treatment Phase 1 only.
Study NCT00523744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Description: Olmesartan medoxomil supplied as 10 mg tablets taken once a day during Treatment Phase 1 only.
Study NCT00523744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine+valsartan
Description: Fixed-dose combination of amlodipine 10 mg plus valsartan 160 mg tablet taken orally once a day during Treatment Phase 2 and Extension Phase.
Study NCT00523744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide (HCTZ) 12.5 mg tablets taken once a day during the Extension Phase.
Study NCT02405676 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone,Vincristine, Cyclophosphamide
Description: Prednisone 45mg/m2, D1\~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1;
Study NCT02405676 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone
Description: Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
Study NCT02405676 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone
Description: Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;
Study NCT03831880 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Genotropin
Description: Genotropin (dose \[mg\] at time of enrollment) given subcutaneously once daily
Study NCT03831880 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: somatrogon
Description: 0.66 mg/kg/week given subcutaneously once weekly
Study NCT02405676 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone
Description: Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
Study NCT02405676 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone
Description: Ifosphamide 1.2g/m2, D1\~5; Etoposide, 100mg/m2, D3\~5; Methotrexate, 5g/m2, D1;Vindelsine 3mg/m2 (MAX 5mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
Study NCT02405676 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab
Description: 375mg/m2, 4 injections for patients in Risk group4; D0 of Protocol AA or BB;
Study NCT03314259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin is a alpha blocker and has a good safety profile that has been used extensively in Urological patients. Potential safety issues would include a minimal risk of orthostatic hypotension and hypersensitivity reaction to tamsulosin in our study population
Study NCT02822274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-70_R84-064)
Study NCT00519220 — intervention group
Intervention type: OTHER
Intervention: Symptom questionnaire
Description: Patients will answer questionnaires evaluating their symptoms of achalasia.
Study NCT01341574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prism adaptation with optical shift of 10 degrees.
Description: Prism adaptation with optical shift of 10 degrees.
Study NCT01341574 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Prism adaptation optical shift of 0 degrees.
Description: Prism adaptation with optical shift of 0 degrees.
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with:Paracetamol
Description: A single dose of each drug will be opened (Paracetamol capsule) or crushed (tablets) in 100 ml of jelly (intervention 1-10) and in 100 ml of apple compote A mix of 6 drugs will be added to 100 ml of jelly (intervention 11) and in 100 ml of apple compote A negative control will consists in 100 ml of plain jelly or apple compote Each participant will receive 24 small transparent plastic glasses (verrines) randomly allocated from number 1 to number 24, each verrine containing 5 ml of the initial 100 ml drug preparation. The participant will be blind to the verrine content.~The participant will taste the verrine content with a 1 ml spoon and spit out each spoonful et rinse his or her mouth with plain water (Evian) between two tests.~The participant will score each verrine numbered 1-24 with a mark ranging from 0 to 10 on the results scoring sheet.~Unblinding will take place immediately after the end of the test. Every volunteer will propose alternative solutions.
Study NCT03314259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo is a tablet made to mimic tamsulosin tablet with same size and colour with no active ingredient
Study NCT02504411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device Assisted Colonoscopy
Description: This will be similar to the standard colonoscopy except the endocuff device will be used.
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with:Paracetamol
Description: A single dose of each drug will be opened (Paracetamol capsule) or crushed (tablets) in 100 ml of jelly (intervention 1-10) and in 100 ml of apple compote A mix of 6 drugs will be added to 100 ml of jelly (intervention 11) and in 100 ml of apple compote A negative control will consists in 100 ml of plain jelly or apple compote Each participant will receive 24 small transparent plastic glasses (verrines) randomly allocated from number 1 to number 24, each verrine containing 5 ml of the initial 100 ml drug preparation. The participant will be blind to the verrine content.~The participant will taste the verrine content with a 1 ml spoon and spit out each spoonful et rinse his or her mouth with plain water (Evian) between two tests.~The participant will score each verrine numbered 1-24 with a mark ranging from 0 to 10 on the results scoring sheet.~Unblinding will take place immediately after the end of the test. Every volunteer will propose alternative solutions.
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Furosemide
Study NCT02504411 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: No endocuff device will be used on the study participants undergoing standard colonoscopy.
Study NCT03137784 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: NVA237 (glycopyrronium bromide)
Description: In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose
Study NCT03137784 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: In each treatment arm, patient will receive placebo
Study NCT02279485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Study NCT01354145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate
Description: Chondroitin sulphate 1200 mg/day, 24 months treatment period
Study NCT01354145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib 200 mg/day, 24 months treatment period
Study NCT01962597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Study NCT01962597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Study NCT01962597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance training
Study NCT01962597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: resistance training
Study NCT02265107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: The program of exercise training (ET) was employed for 6 consecutive months with 3 sessions per week. The training of physical activity consisted of a combination of aerobic and resistance exercises for upper and lower limbs. Each session included: (1) 5-minute warm-up, (2) 30 minutes of aerobic exercise (performed in treadmills and stationary bikes); (3) 20 minutes of resistance exercises with dumbbells for upper limbs and ankle support for lower limbs (exercises preformed in diagonals) that consisted of 6 sets of 10 resistance exercises repeated for upper limbs, and the same number of sets for lower limbs; and (4) 5-minute cool-down, totaling ninety minutes of session per day (90min/day) and, two hundred and seventy minutes per week (270min/week).
Study NCT01958385 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: placement of g-Cath EZ suture anchors
Study NCT01958385 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Furosemide
Study NCT02377570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERANOVA 400 dialyzer prototype AA
Description: Hemodialysis
Study NCT02377570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERANOVA 400 dialyzer prototype BB
Description: Hemodialysis
Study NCT02377570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERNOVA 400 dialyzer prototype CC
Description: Hemodialysis
Study NCT02377570 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FX CorDiax 80 dialyzer
Description: Hemodialysis
Study NCT03444766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose on specified days
Study NCT01504633 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA/EPA and iron supplementation
Description: 24-week supplementation consisting of daily dosage of DHA/EPA or placebo capsule and iron/placebo syrup Capsule: DHA/EPA (100mg DHA + 20mg per day) or placebo Syrup: Fe syrup (16mg elemental iron per day) or placebo
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Levothyroxine sodium salt
Study NCT03395301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coil
Description: Fiber platinum coil were inserted into the interstitial part of the tubes of patients in hydrosalpinx through hysteroscopy
Study NCT00867776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AAHC Exercise Program Support Group
Description: 6-week community-based, culturally tailored support group program, focusing on exercise and healthy lifestyle habits. Groups will also include basic psychoeducation about depression and depression care. Groups will have up to 20 participants and will meet weekly for 2 hours. By the end of the program, participants will be encouraged to create a personalized action plan focusing on exercise and other healthy lifestyle choices.
Study NCT03373032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stiper
Description: Stiper silicon tablets, for acupunture's stimulation of meridian points, the Stiper's chemical composition is nothing more than SiO 2 - (silicon dioxide) the shape of the quartz stone (silicon rich).They will perform the treatment with the Stiper silicon inserts, which will be applied and fixed by plasters at the acupuncture points, duration of 05 minutes.
Study NCT03373032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Treatment with a systemic needle to stimulate meridian acupuncture points, treatment begins with asepsis with 70% alcohol-soaked cotton in the region of the acupoints and then sterile and disposable needles (0.25 mm x 30 mm) will be inserted in both limbs, will be placed in the following regions: shoulders, thorax, legs and feet with the puncture order from bottom to top,duration of 30 minutes.